A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer

NCT05055232 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

114

Enrollment

INDUSTRY

Sponsor class

Conditions

ROS1 Rearrangement Non-small Cell Lung Cancer
ALK Rearrangement Non-small Cell Lung Cancer

Interventions

DRUG: XZP-3621

Sponsor

Xuanzhu Biopharmaceutical Co., Ltd.